股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年5月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年6月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 | RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 | RMB | ...

一、股东股份质押及解除质押的基本情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）近日接到公 司实际控制人楼小强先生和郑北女士的函告，获悉楼小强先生和郑北女士将其所 持有的公司部分股份进行了质押和解除质押，具体情况如下： | | 是否为控 | | | 占公 | | 是否 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押 | 占其所 | 司总 | 是否 | 为补 | 质押起 | | 质押到 | | | 质押用 | | 名称 | 第一大股 | 数量 | 持股份 | 股本 | 为限 | 充质 | 始日 | | 期日 | | 质权人 | 途 | | | 东及其一 | （股） | 比例 | | 售股 | | | | | | | | | | 致行动人 | | | 比例 | | 押 | | | | | | | | | 实际控制 | | | | | | 2025 | 年 | 2026 | 年 | 中信证 券股份 | 置换存 量金融 | | ...

Group 1 - The core point of the news is that 康龙化成 (Pharmaron) has seen a stock increase of over 4% following the announcement of its investment in a healthcare fund [1] - 康龙化成's subsidiary, Pharmaron UK Limited, plans to invest $30 million in the BLC Healthcare USD Fund I L.P. as a limited partner [1][2] - The fund aims to raise approximately $100 million to invest in various securities and assets in the global biopharmaceutical and life sciences sectors, focusing on early and growth-stage projects for long-term capital appreciation [2] Group 2 - The investment will utilize the expertise of professional investment institutions in the biopharmaceutical industry [1] - The fund will have the discretion to invest in other investment funds or vehicles managed by third parties [2] - The investment strategy includes a wide range of securities, including equity, debt securities, and derivatives [2]

Group 1 - The company 康龙化成 (300759) announced that its wholly-owned subsidiary 康龙英国 plans to invest $30 million in BLC Healthcare USD Fund I L.P. using its own funds [1] - The target fundraising amount for the BLC Healthcare USD Fund I L.P. is approximately $100 million [1] - As of the announcement date, 康龙英国 is the largest contributor to the fund, with a subscription ratio of 85.71% [1]

证券代码：300759 证券简称：康龙化成 公告编号：2025-029 康龙化成（北京）新药技术股份有限公司 关于境外子公司参与境外股权投资基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、投资事项概述 为充分运用专业投资机构在生物医药行业内投资、研判的能力，康龙化成（北 京）新药技术股份有限公司（以下简称"公司"）的全资子公司 Pharmaron UK Limited（以下简称"康龙英国"）拟作为有限合伙人以自有资金认缴出资 3,000 万美元参与投资 BLC Healthcare USD Fund I L.P.（以下简称"基金"或"合伙企 业"）。2025 年 5 月 30 日，康龙英国签署了《Amended and Restated Agreement of Exempted Limited Partnership of BLC Healthcare USD Fund I L.P.》（以下简称 "《合伙协议》"）。 本次交易不构成关联交易，不构成《上市公司重大资产重组管理办法》规定 的重大资产重组情况。根据《深圳证券交易所创业板股票上市规则 ...

Group 1 - The company is a global leader in the one-stop CRDMO service platform, providing comprehensive services for drug discovery, preclinical and clinical development, and commercial production for various therapies since its IPO in 2019 [1] - The company's revenue is expected to grow at a CAGR of 27.13% from 2018 to 2024, while net profit attributable to the parent company is projected to grow at a CAGR of 32.39% during the same period [1] - The number of projects and new order amounts continue to increase, with new orders expected to grow over 20% year-on-year in 2024, ensuring stable performance for the company [1] Group 2 - The global pharmaceutical R&D market remains robust, with strong outsourcing demand for CXO services [1] - According to Frost & Sullivan, the global market sizes for drug discovery CRO, clinical CRO, and CDMO in 2022 were $180 billion, $547 billion, and $749 billion, respectively, and are projected to grow to $359 billion, $818 billion, and $1,573 billion by 2027, with respective 5-year CAGRs of 14.8%, 8.4%, and 16.0% [1] - China's CXO companies are expected to increase their market share in global drug discovery CRO, clinical CRO, and CDMO from 17.7%, 10.8%, and 13.2% in 2022 to 25.3%, 22.2%, and 21.2% by 2027 [1] Group 3 - The company maintains a customer-oriented approach, with 74.84% of revenue in 2024 coming from clients using multiple services [2] - The company introduced over 900 new clients in 2024, contributing to 5.34% of revenue [2] - The company has established 21 operational entities globally, including 11 overseas, enhancing customer communication and reducing geopolitical risks [2] Group 4 - The company is expected to achieve revenues of 136.38 billion, 154.47 billion, and 176.27 billion yuan from 2025 to 2027, with growth rates of 11.10%, 13.26%, and 14.12% respectively [2] - Net profit attributable to the parent company is projected to be 18.15 billion, 21.18 billion, and 25.41 billion yuan for the same period, with growth rates of 1.20%, 16.69%, and 19.98% respectively [2] - The company is rated as a "buy" due to its unique integrated CRDMO capabilities and sufficient order backlog [2]

Pharmaron Beijing Co., Ltd. 康龙化成（北京）新药技术股份有限公司 2025 H Share Award and Trust Scheme 2025年H股奖励信托计划 1 Table of Contents 目录 | 1. | Definitions and Interpretation 定义和解释 | 1 | | --- | --- | --- | | 2. | General Introduction and Purpose of the Scheme 本计划概览与目的 | 5 | | 3. | Conditions 条件 | 7 | | 4. | Duration 期限 | 7 | | 5. | Administration 管理 | 7 | | 6. | Selection of Selected Participant 选定参与者的选择 | 10 | | 7. | Award Letter regarding Grant of Awards 奖励授予的奖励函 | 15 | | 8. | Receipt of Treasury H Shares by the Trustee ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-028 康龙化成（北京）新药技术股份有限公司 关于召开 2024 年年度股东大会、2025 年第一次 A 股类别股 2、股东大会的召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会的召集、召开程序符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的时间： （1）现场会议召开时间：2025 年 6 月 20 日（星期五）13:30； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 6 月 20 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通 过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 6 月 20 日 9:15-15:00。 5、会议的召开方式： 东大会及 2025 年第一次 H 股类别股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 3 月 26 日召开的第 ...

Group 1 - The major shareholder, Xincheng Kangcheng, plans to reduce its stake in Kanglong Chemical (300759) by up to 26.67 million shares, which represents 1.50% of the company's total share capital [1]

公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）及其一致行 动人深圳市信中龙成投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于近日收到 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）（以下简称"信 中康成"）及其一致行动人深圳市信中龙成投资合伙企业（有限合伙）（以下简称 "信中龙成"）出具的《股份减持计划告知函》。信中康成持有公司股份 250,161,242 股，占公司总股本（即 1,778,195,525 股）的 14.07%。信中康成计划 自本公告披露之日起 15 个交易日（2025 年 6 月 10 日）后的 3 个月内以集中竞 价交易或大宗交易等深圳证券交易所认可的合法方式减持公司股份不超过 26,672,932 股（占公司总股本的 1.50%）。 证券代码：300759 证券简称：康龙化成 公告编号：2025-027 根据 2020 年 3 月 6 日中国证监会发布的《上市公司创 ...